Accretropin Approval History
- FDA approved: Yes (First approved January 23rd, 2008)
- Brand name: Accretropin
- Generic name: somatropin (rDNA origin)
- Dosage form: Subcutaneous Injection
- Company: Cangene
- Treatment for: Pediatric Growth Hormone Deficiency, Turner's Syndrome
Accretropin (somatropin (rDNA origin)) is recombinant human growth hormone indicated for treatment of pediatric patients who have growth failure due to an inadequate secretion of normal endogenous growth hormone, or treatment of short stature associated with Turner Syndrome in pediatric patients whose epiphyses are not closed.
Development History and FDA Approval Process for Accretropin
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.